Russia Tests Groundbreaking Meningococcal Vaccine with Rare Serogroup B

Russia has started trials for a new meningococcal vaccine in Nizhny Novgorod. The vaccine stands out because it includes a rare serogroup B component. If successful, mass production could begin as early as next year. The vaccine is a pentavalent formulation, meaning it targets five different strains of meningococcal bacteria. Most vaccines of this type do not include protection against serogroup B, which is harder to develop. Testing is currently focused on Nizhny Novgorod to assess how well it works in real-world conditions.

Developers aim to confirm the vaccine’s safety and effectiveness before scaling up. If the trials go well, factories will prepare for large-scale manufacturing. This would make Russia one of the few countries producing a vaccine with serogroup B coverage.

The trial in Nizhny Novgorod marks a key step toward wider availability of the vaccine. Once mass production starts, it could help prevent outbreaks of meningococcal disease across Russia. The inclusion of serogroup B also fills a gap in current vaccination options.